India’s pharmaceutical major Sun Pharma is among nine midsize global drug manufacturers that have signed voluntary pricing agreements with the Trump administration. The move is part of the White House’s aggressive expansion of its most-favored-nation (MFN) pricing push, aimed at aligning U.S. medicine prices with those of other developed economies.
Expanding the MFN Pricing Regime
The latest agreements include midsize players such as Sun Pharma, Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Teva Pharmaceuticals, and UCB.
This follows earlier MFN deals secured with 17 major pharmaceutical giants, including Pfizer, AstraZeneca, Merck, Eli Lilly, and Novo Nordisk. “We now have 26 companies representing 90 per cent of the domestic pharmaceutical market, and the other 10 per cent are also coming in [to make deals]. They have no choice,” President Donald Trump remarked during the announcement.
Key Terms of the Agreement
While comprehensive details on the financial impact remain limited—raising concerns across the industry regarding how price concessions might affect smaller players—reports from The Washington Post outline several core commitments:
-
Lower Drug Prices: Participating manufacturers will reduce prices on specialized treatments, including therapies for cancer, Parkinson’s disease, glaucoma, liver disease, and hemophilia.
-
Medicaid Alignment: Companies will extend MFN pricing to state Medicaid programs.
-
Stockpile Contributions: Firms like Sun Pharma and Astellas Pharma are required to donate substantial quantities of their products to the U.S. Strategic Active Pharmaceutical Ingredients Reserve. According to the White House, this measure is designed to reduce reliance on foreign nations and secure domestic emergency medical supplies.
-
U.S. Manufacturing Investments: The participating drugmakers have committed to investing at least $19.6 billion toward near-term domestic manufacturing infrastructure.
In exchange for these concessions, the drugmakers are expected to bypass the administration’s proposed tariffs and newly instituted Medicare drug pricing models.
